Table 2 IgG antibody responses (22F-ELISA) against individual pneumococcal vaccine serotypes and cross-reactive serotypes 6A and 19A (ATP immunogenicity cohort)
PHiD-CV group | Control group | ||||||
|---|---|---|---|---|---|---|---|
PHiD-CV serotypes | N | % ≥ 0.2 μg/mL (95% CI) | GMC, μg/mL (95% CI) | N | % ≥ 0.2 μg/mL (95% CI) | GMC, μg/mL (95% CI) | |
1 | Pre-vaccine | 204 | 19.6 (14.4-25.7) | 0.07 (0.06-0.09) | 110 | 18.2 (11.5-26.7) | 0.07 (0.06-0.09) |
Post-dose 3 | 217 | 100 (98.3-100) | 2.69 (2.42-2.99) | 108 | 1.9 (0.2-6.5) | 0.03 (0.03-0.03) | |
4 | Pre-vaccine | 209 | 14.8 (10.3-20.4) | 0.07 (0.06-0.08) | 112 | 16.1 (9.8-24.2) | 0.07 (0.06-0.08) |
Post-dose 3 | 217 | 100 (98.3-100) | 3.44 (3.06-3.87) | 112 | 2.7 (0.6-7.6) | 0.03 (0.03-0.03) | |
5 | Pre-vaccine | 210 | 17.6 (12.7-23.5) | 0.07 (0.06-0.08) | 111 | 19.8 (12.9-28.5) | 0.07 (0.05-0.08) |
Post-dose 3 | 217 | 100 (98.3-100) | 4.17 (3.75-4.63) | 109 | 3.7 (1.0-9.1) | 0.03 (0.03-0.04) | |
6B | Pre-vaccine | 205 | 21.0 (15.6-27.2) | 0.09 (0.07-0.10) | 111 | 31.5 (23.0-41.0) | 0.10 (0.08-0.12) |
Post-dose 3 | 217 | 82.0 (76.3-86.9) | 0.95 (0.76-1.20) | 112 | 1.8 (0.2-6.3) | 0.03 (0.03-0.03) | |
7F | Pre-vaccine | 207 | 27.1 (21.1-33.6) | 0.09 (0.08-0.11) | 111 | 23.4 (15.9-32.4) | 0.08 (0.07-0.10) |
Post-dose 3 | 217 | 99.5 (97.5-100) | 3.33 (2.99-3.71) | 110 | 1.8 (0.2-6.4) | 0.03 (0.03-0.04) | |
9V | Pre-vaccine | 208 | 38.5 (31.8-45.4) | 0.13 (0.11-0.16) | 110 | 39.1 (29.9-48.9) | 0.15 (0.11-0.19) |
Post-dose 3 | 217 | 97.2 (94.1-99.0) | 2.39 (2.06-2.76) | 112 | 9.8 (5.0-16.9) | 0.04 (0.03-0.05) | |
14 | Pre-vaccine | 206 | 87.9 (82.6-92.0) | 0.75 (0.64-0.89) | 110 | 84.5 (76.4-90.7) | 0.76 (0.60-0.97) |
Post-dose 3 | 217 | 99.1 (96.7-99.9) | 3.80 (3.24-4.46) | 112 | 35.7 (26.9-45.3) | 0.14 (0.11-0.17) | |
18C | Pre-vaccine | 204 | 36.3 (29.7-43.3) | 0.12 (0.10-0.15) | 110 | 34.5 (25.7-44.2) | 0.12 (0.09-0.15) |
Post-dose 3 | 217 | 99.5 (97.5-100) | 10.01 (8.49-11.80) | 112 | 3.6 (1.0-8.9) | 0.03 (0.03-0.04) | |
19F | Pre-vaccine | 208 | 68.3 (61.5-74.5) | 0.33 (0.28-0.40) | 111 | 68.5 (59.0-77.0) | 0.36 (0.29-0.45) |
Post-dose 3 | 217 | 98.6 (96.0-99.7) | 7.65 (6.55-8.93) | 111 | 22.5 (15.1-31.4) | 0.08 (0.07-0.10) | |
23F | Pre-vaccine | 202 | 29.2 (23.0-36.0) | 0.08 (0.07-0.10) | 108 | 31.5 (22.9-41.1) | 0.10 (0.07-0.12) |
Post-dose 3 | 217 | 87.6 (82.4-91.6) | 1.10 (0.91-1.33) | 112 | 2.7 (0.6-7.6) | 0.03 (0.03-0.04) | |
Cross-reactive serotypes | |||||||
6A | Pre-vaccine | 208 | 34.1 (27.7-41.0) | 0.13 (0.11-0.15) | 112 | 35.7 (26.9-45.3) | 0.14 (0.11-0.18) |
Post-dose 3 | 217 | 25.8 (20.1-32.2) | 0.09 (0.08-0.11) | 108 | 7.4 (3.3-14.1) | 0.04 (0.04-0.05) | |
19A | Pre-vaccine | 205 | 48.3 (41.3-55.4) | 0.18 (0.15-0.22) | 110 | 44.5 (35.1-54.3) | 0.20 (0.15-0.26) |
Post-dose 3 | 217 | 43.8 (37.1-50.7) | 0.15 (0.13-0.18) | 108 | 13.9 (8.0-21.9) | 0.06 (0.05-0.07) | |